Dixie Brands launched a line of health and wellness products in late 2015 under the brand name Aceso. The herbal supplements contain cannabinoids derived from industrial hemp. New Zealand has approved this supplement for use by a single individual, as Associate Health Minister Peter Dunne received an application on April 1st from a patient with Tourette’s Syndrome and approved it today. He had previously approved an Elixinol product last year.
Dunne approved the spray because it has fewer side effects than Sativex, which is sold by GW Pharma (NASDAQ: GWPH), and because it met 7 out of 8 criteria. Aceso Calm, according to the company, has 335mg of cannabinoids per 1 oz. bottle (5mg of CBD per spray) and includes terpenes limonene and linalool as well as passionflower extract and CoQ10.
Read Jo Moir’s “Peter Dunne approves cannabis product for Tourette’s Syndrome patient”: http://www.stuff.co.nz/national/health/78546650/peter-dunne-approves-new-cannabis-product-for-patient-with-tourettes-syndrome
